Drug Profile
BI 730460
Alternative Names: BI-730460Latest Information Update: 08 Apr 2019
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antipsoriatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 10 Aug 2022 Boehringer Ingelheim terminates a phase I trial in Psoriasis (In volunteers) in Germany (NCT03483077)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Psoriasis in Germany (PO, Liquid)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Psoriasis(In volunteers) in Germany (PO, Tablet)